Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q1 FY2023 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation
Slide 1: Branded IPR-driven Pharma Player in Frontier Markets
Branded IPR-driven Pharma Player in Frontier Markets Q1FY23 Financial Results
Slide 2: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 3: Contents
Contents 04 Corporate Snapshot 15 Financial Highlights 21 Strategic Roadmap 3
Slide 4: Bridging the Supply Gap in Frontier Markets
Bridging the Supply Gap in Frontier Markets Branded IPR-based pharma Presence in OTC segments including company strong branded generics portfolio Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast portfolio across diverse Backed by deep distributi
Slide 5: Successful Produce, Stock, Sell Business Model
Successful Produce, Stock, Sell Business Model Established operations: Expansion initiated: Guatemala (Latin America), Dominican Republic El Salvador, Nicaragua, Ecuador, Chile Markets (Caribbean) and Angola (Africa) (Latin America) New operations: Honduras (Latin America) Central African Republic,
Slide 6: Key Success Factors
Key Success Factors Market Selection Methodology Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep
Slide 7: Transition from “Asset Light” to “Asset Right”
Transition from “Asset Light” to “Asset Right” Marketing and Market Research Product Identification Product Registration Manufacturing Distribution Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to ‘Asset Right’
Slide 8: Investment in Manufacturing Facilities
Investment in Manufacturing Facilities Setting up EU GMP compliant pharma manufacturing unit General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Production from Pharma
Slide 9: Global Footprint
Global Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9
Slide 10: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 11: Corporate Structure
Corporate Structure Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African Angola LDA SRL (WOS) S.A
Slide 12: Experienced Board of Directors
Experienced Board of Directors Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of rich Chartered Accountant with 15 years’ generation entrepreneur, qualified experience with
Slide 13: Strong Leadership Team
Strong Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associate
Slide 14: Regional Teams
Regional Teams Jignesh Dinesh Kumar Shah Laksh Shewakramani Ram Chawla Financial Controller – Angola Compliance Head – Angola Country Head – Angola Pankaj Singh Manish Jumnani Head of Operations– Guatemala Sales Head – Guatemala Karan Kapoor Bharat Jawarani Head of Operations – Sales Head – Dominica
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS Balaxi
Slide 16: Management’s Comments
Management’s Comments “Our revenue growth of 42% during Q1 is driven by strong volume contribution from Latin American markets. We have also derived translation benefits from a strong currency in Angola. Gross margin expanded significantly, once again based on the strength of the growing Latin Ameri
Slide 17: Quarterly Financial Performance
Quarterly Financial Performance Particulars (INR Crore) Q1FY23 Q1FY22 YoY Revenue 82.78 58.34 +41.9% Gross Profit 34.52 16.8 +105.5% Gross Margin % 41.7% 28.8% 1,290 bps EBITDA 17.03 12.55 +35.6% EBITDA Margin % 20.6% 21.5% (95) Bps Profit After Tax 14.15 10.71 +32.1% PAT Margin % 17.1% 18.4% (127)
Slide 18: Pharma Product Mix – Q1 FY23
Pharma Product Mix – Q1 FY23 Geographies Products 1% Angola Shareholders’ 22% Debt Fixed Assets Working Capital Funds Guatemala 35% Branded Dominican Generics 15% 62% Republic 65% Honduras Dosage Forms Therapeutic Areas 12% Tablets Antibiotics 36% 37% 14% Injectables Analgesic 47% Liquids Anti-malar
Slide 19: Historical Financial Performance
Historical Financial Performance Particulars (INR Crore) FY22 FY21 YoY Revenue 279.39 231.33 +20.8% Gross Profit 83.79 59.19 +41.6% Gross Margin % 30.0% 25.6% +440 bps EBITDA 55.18 44.64 +23.6% EBITDA Margin % 19.7% 19.3% +45 bps Profit After Tax 47.66 38.14 +25.0% PAT Margin % 17.1% 16.5% +60 bps E
Slide 20: Pharma Product Mix – FY22
Pharma Product Mix – FY22 Geographies Products Shareholders’ Angola 28% Debt Fixed Assets Working Capital Funds 30% Guatemala Branded Generics 59% 13% Dominican Republic 70% Dosage Forms Therapeutic Areas 12% Tablets Antibiotics 31% Injectables 41% 13% 46% Analgesic Liquids Anti-malaria 12% Capsules
Slide 21: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation Presence across Angola, Guatemala and Dominican Republic Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-22: Expansion into New Geographies Aim to cap
Slide 22: Thank You
Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact Mr. Sunny Purohit +91-40-2355-5300 sunny@balaxi.com www.balaxipharma.in BALAXI BALAXI:IN Thank You
Balaxi Pharmaceuticals — Q1 FY2023 Earnings Presentation on 6ix